޵ʴ
/̿
ֺ ī̸ġ, Ǽȯ Ǻΰ ѷġ 16 10 7.5 Ǻΰ ȿľó, Ǽġ 㰡
ƮŰ Ʈ̱ Ʈϱ Ϻ Űϱ
2019.12.04  09:51:45
Ʈ ̽ ̹ msn
   
ī̸ġ ǰ ΰ

۷ι ̿ ѱֺ(ǥ̻ ҿ) ڻ ͷŲ-23(IL-23) ī̸ġʵø(Skyrizi, и Űָ, Risankizumab) Ǵ ġ( ) ʿ ϴ ߵ ǻ Ǽġ 3ڷ ǰǾǰó 㰡 ޾Ҵٰ .

̹ 㰡 ٰŰ UltIMMa-1 UltIMMa-2 ӻ󿬱 16 Ǻΰ , ȯ κ(82%, 81%) 1(52) Ŀ Ǽ Ǻΰ 90% ϰ ư(PASI 90), ټ(56%, 60%) ȯڰ Ǽ Ǻΰ ϰ (PASI 100).

д缭б Ǻΰ “ Ǽ ü, , ȸ ɰ ִ ȯ, ȯڿ ġ ̰ ϰ, Ⱓ ġԿ پ ۿ ϰ ȴ” “ī̸ġ 3 ӻ 16 90%̻ ȯ 80% 1 Ŀ ȣ ¸ Ǽȯ ġḦ ο ġ ɼ ”̶ ߴ.

ī̸ġ 뷮 0, 4 150mg ֻ ϰ, Ŀ 12ָ Ѵ. Ե IL-23迭 ʷ 4ȸ ּ Ƚ ްų ڰ ֻ ִ.

ѱֺ к ̻ “ī̸ġ Ǽ ȯڵ ϴ Ǻο ȿ Ⱓ , Ǽ̶ η ġ, ̹ 㰡 Ǽ Ǻ ȿ ϴ Ǽ ȯ ġῡ ߿ ǥ ”̶ “ֺ ī̸ġ 鿪 о μ Ǽ ȯڵ 䱸 ϴ Ʈ Ȯϰ, Ǽ 鿪 Ű ȯ ġ ”̶ ߴ.

ī̸ġ 鿪 Ű ȯ ߰ IL-23 ϴ , IL-23 p19 IL-23 ü ϴ Ѵ.

ī̸ġ 2109 ȯڸ 4 ӻ(UltIMMa-1, UltIMMa-2, IMMvent IMMhance) ġ ȿ 򰡵ƴ. UltIMMa-1 UltIMMa-2 , 16 ī̸ġ ġ ȯ 75% 90% Ǻ (PASI 90) ޼(placebo 5%, 2%, P<0.001), 100% Ǻ (PASI 100) ޼ ȯ 36%, 51% Ÿ(placebo 0%, 2%, P<0.001). ī̸ġ ȯڸ м , 16ֽ 90% Ǻ 100% Ǻ ȯ κ 1 ġ Ÿ(PASI 90 PASI 100 88%, 80%).

1 κ ȯڿ Ǻΰ ǰ, ȿ ȯڰ Բ 6 24ȸ Ǻΰȸ(24th World Congress of Dermatology, WCD) 2 ǥƴ. IMMhance ī̸ġ 2 (ִ 104) ȿ Ͱ õ ̴. 28 Ǻΰ ų(sPGA 0: static Physician Global Assessment 0) Ǻΰ (sPGA 1) ȯڱ ī̸ġ ޾౺ ٽ ش ī̸ġ 73% 72% 94 Ŀ Ǻ ȿ(sPGA 0, PASI 100) Ÿ. ݸ, ޾౺ ȯ 7% 4% (p<0.001).

Ǽ 鿪 ̻ ߻ϴ Ǻȯ, Ȳġ, , к μ ȫ Ѵ. 츮 3% ϴ ߼̸, 150 ȯڰ ִ ˷ ִ. Ư Ǽ ȯڵ , 巯 ȸ ߰ ޴ 찡 . ̷ ȸ δ ɸ Ʈ , ȭ ߱ ֱ Ȯϰ ġᰡ ʿϴ.

, ī̸ġ 3 Ϻ Ļ뵿(MHLW) ġ ȿ ǻ Ǽ, Ǽ, ȫ Ǻ Ǽ Ǽ ȯ ġῡ ù 㰡 , 4 ̱ ǰǾ౹(FDA) ȸ(EC) ߵ ǻ Ǽ ȯ ġῡ ޾Ҵ.

ī̸ġ ΰӰ ֺ ϰ ִ ǰ ϳ, ֺ ߰ ۷ι ǸŸ Ѵ.

 

< ۱ © ޵ʴ >
ٸ   
ƮŰ Ʈ̱ Ʈϱ Ϻ Űϱ
Ʈ ̽ ̹ msn ڷΰ ΰ
̾߱ (0)
ڵϹ ڵ带 Էϼ!   
Ȯ
- 200ڱ ֽϴ. ( 0 byte / ִ 400byte)
- 弳 νŰݼ մϴ. [Ģ]
̾߱ (0)


ŹҰŰ̿ԽùĢ޹ħ̸Ϲܼźûҳ⺸ȣå( : ȫ )
ּ : 617-18 HS  |  ǥȭ : (02)978-1114  |  ѽ : (02)978-8307
ȣ : ޵ʴ  |  Ⱓ๰Ϲȣ : 00011  |   : 2005 8 8(â:2004 3 15)
ڵϹȣ : 210-81-12137  |  / : ջ
Copyright © 2012 www.medipharmnews.com. All rights reserved. Powered by MedipharmNews Since 2004